AuditorApr 13, 2026, 06:01 PM
AIM ImmunoTech Receives Going Concern Audit Opinion for FY2025
AI Summary
AIM ImmunoTech Inc. announced its independent auditor included a "going concern emphasis of matter" in its audit report for the fiscal year ended December 31, 2025. This disclosure is mandated by NYSE American. Despite this, management expressed confidence in its ability to raise funds, citing positive progress in the Phase 2 DURIPANC clinical study for Ampligen in late-stage pancreatic cancer, with the next update expected in June 2026.
Key Highlights
- Audit report for FY2025 included a going concern emphasis of matter.
- Management confident in ability to raise funds.
- Positive progress in Phase 2 DURIPANC study for Ampligen.
- Next DURIPANC study update expected in June 2026.